SSMX.F Stock Overview
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 1/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Sysmex Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥15.95 |
52 Week High | JP¥23.78 |
52 Week Low | JP¥15.95 |
Beta | 0.52 |
1 Month Change | -13.88% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -55.90% |
5 Year Change | -13.37% |
Change since IPO | 27.93% |
Recent News & Updates
Recent updates
Shareholder Returns
SSMX.F | US Medical Equipment | US Market | |
---|---|---|---|
7D | 0% | 1.8% | 1.2% |
1Y | n/a | -0.5% | 24.9% |
Return vs Industry: Insufficient data to determine how SSMX.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how SSMX.F performed against the US Market.
Price Volatility
SSMX.F volatility | |
---|---|
SSMX.F Average Weekly Movement | n/a |
Medical Equipment Industry Average Movement | 7.2% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SSMX.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SSMX.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1968 | 9,500 | Hisashi Ietsugu | www.sysmex.co.jp |
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.
Sysmex Corporation Fundamentals Summary
SSMX.F fundamental statistics | |
---|---|
Market cap | US$9.97b |
Earnings (TTM) | US$289.55m |
Revenue (TTM) | US$2.82b |
34.4x
P/E Ratio3.5x
P/S RatioIs SSMX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SSMX.F income statement (TTM) | |
---|---|
Revenue | JP¥438.28b |
Cost of Revenue | JP¥205.29b |
Gross Profit | JP¥232.99b |
Other Expenses | JP¥187.93b |
Earnings | JP¥45.06b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
Earnings per share (EPS) | 72.27 |
Gross Margin | 53.16% |
Net Profit Margin | 10.28% |
Debt/Equity Ratio | 6.1% |
How did SSMX.F perform over the long term?
See historical performance and comparison